Trial Search Results

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seagen Inc.

Stanford Investigator(s):


  • Drug: SGN-75
  • Drug: everolimus


Phase 1


Inclusion Criteria:

   - Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression

   - Previously treated with at least 1 tyrosine kinase inhibitor (TKI)

   - Measurable disease

   - Eastern Cooperative Oncology Group performance status 0 or 1

   - Adequate lung and renal function

Exclusion Criteria:

   - Prior treatment with anti-CD70-directed therapy

   - Received more than one prior treatment with an mTOR inhibitor

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting